Supernus Pharmaceuticals, Inc. (SUPN)

Market Cap	2.22B
Revenue (ttm)	668.00M
Net Income (ttm)	61.91M
Shares Out	62.62M
EPS (ttm)	1.11
PE Ratio	32.08
Forward PE	18.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	858,509
Open	34.85
Previous Close	35.10
Day's Range	34.85 - 35.69
52-Week Range	27.05 - 40.28
Beta	0.70
Analysts	Hold
Price Target	36.00 (+1.38%)
Earnings Date	Aug 5, 2025

About ATVI

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 1, 2012
• Employees: 674
• Stock Exchange: NASDAQ
• Ticker Symbol: SUPN
• Website: https://www.supernus.com

Financial Performance

In 2024, Supernus Pharmaceuticals's revenue was $661.82 million, an increase of 8.94% compared to the previous year's $607.52 million. Earnings were $73.87 million, an increase of 5512.84%.

Analyst Summary

According to 2 analysts, the average rating for SUPN stock is "Hold." The 12-month stock price target is $36.0, which is an increase of 1.38% from the latest price.

Price Target

$36.0

(1.38% upside)

Analyst Consensus: Hold